Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

"We actually believe that we have an oral here that could generate the same amount of weight loss as you see with Wegovy or Ozempic, but in a pill," Jonsson added, echoing what Eli Lilly CEO Dave ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...